Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 28, 2022 06:35 ET | Source: Axsome Therapeutics, Inc.

Axsome Therapeutics Announces AXS-05 Achieves Primary Endpoint in the ACCORD Phase 3 Trial in Alzheimer’s Disease Agitation

AXS-05 statistically significantly delayed time to relapse of Alzheimer’s disease agitation versus placebo (p=0.014, primary endpoint) AXS-05 statistically significantly prevented relapse of...
September 08, 2022 07:00 ET | Source: Axsome Therapeutics, Inc.

Axsome Therapeutics Initiates ADVANCE-2 Phase 3 Trial of AXS-05 in Alzheimer’s Disease Agitation

NEW YORK, Sept. 08, 2022 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous...
June 02, 2022 07:00 ET | Source: Axsome Therapeutics, Inc.

Axsome Therapeutics Presents New Data from the GEMINI Trial Demonstrating Efficacy of AXS-05 on Anhedonia in Patients with Major Depressive Disorder

AXS-05 rapidly and significantly improved anhedonic symptoms, measured by the MADRS anhedonia subscale, starting 1 week after treatment Data being presented at the American Society of Clinical...
June 01, 2022 07:00 ET | Source: Axsome Therapeutics, Inc.

Axsome Therapeutics Announces Late-Breaking Presentations of Positive Results of the EVOLVE Trial of AXS-05 in Major Depressive Disorder After Prior Treatment Failures at the American Society of Clinical Psychopharmacology (ASCP) 2022 Annual Meeting

Rapid, substantial, and durable improvement in depressive symptoms (MADRS), and functioning (SDS) with AXS-05, sustained over 12 months, (p<0.001 for all vs. baseline) Rapid, substantial, and...
May 31, 2022 07:39 ET | Source: Axsome Therapeutics, Inc.

Axsome Therapeutics Announces Publication of Pivotal GEMINI Phase 3 Trial of AXS-05 in Major Depressive Disorder in The Journal of Clinical Psychiatry

NEW YORK, May 31, 2022 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous...
March 02, 2022 07:00 ET | Source: Axsome Therapeutics, Inc.

Axsome Therapeutics to Present at the Cowen 42nd Annual Health Care Conference

NEW YORK, March 02, 2022 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing novel therapies for the management of central nervous system (CNS)...
February 15, 2022 07:00 ET | Source: Axsome Therapeutics, Inc.

Axsome Therapeutics to Report Fourth Quarter and Full Year 2021 Financial Results on March 1, 2022

Axsome to host conference call and webcast on Tuesday, March 1, 2022 at 8:00 AM Eastern Time NEW YORK, Feb. 15, 2022 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a...
February 11, 2022 07:00 ET | Source: Axsome Therapeutics, Inc.

Axsome Therapeutics to Present at the 11th Annual SVB Leerink Global Healthcare Conference

NEW YORK, Feb. 11, 2022 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing novel therapies for the management of central nervous system (CNS)...
August 23, 2021 06:00 ET | Source: Axsome Therapeutics, Inc.

Axsome Therapeutics Provides Update on the New Drug Application for AXS-05 for the Treatment of Major Depressive Disorder

NEW YORK, Aug. 23, 2021 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing novel therapies for the management of central nervous system (CNS)...
August 09, 2021 07:05 ET | Source: Axsome Therapeutics, Inc.

Axsome Therapeutics Reports Second Quarter 2021 Financial Results and Provides Business Update

Company to host conference call today at 8:00 AM Eastern NEW YORK, Aug. 09, 2021 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing novel therapies...

Next Page keyboard_arrow_right